Acute myeloid leukemia · 20 regimens
Cost vs Efficacy
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Midostaurin monotherapy Variant #01 | FLT3 | R 152 836 | 28d | — | — | ~2 | ~R 305 671 indirect | — |
CLAG-M Variant #01 | — | R 66 420 | 6d | — | — | ~1 | ~R 66 420 indirect | — |
CLAG Variant #01 | — | R 57 442 | — | — | — | ~1 | ~R 57 442 indirect | — |
FLAG-Ida Variant #01 | — | R 48 325 | 28d | — | 5.4 mo | 1 | R 48 325 PFS proxy | 3 |
F-SHAI Variant #01 | — | R 47 713 | 11d | — | — | ~1 | ~R 47 713 indirect | — |
FLAG Variant #01 | — | R 47 479 | — | — | ~6.7 mo | ~2 | ~R 94 958 PFS proxy · indirect | 1 |
Gemtuzumab ozogamicin monotherapy Variant #04 | — | R 28 653 | 8d | — | ~4.9 mo | ~8 | ~R 229 221 PFS proxy · indirect | 1 |
SHAI Variant #01 | — | R 25 707 | 11d | — | — | ~1 | ~R 25 707 indirect | — |
MAC Variant #01 | — | R 25 420 | 6d | — | — | ~1 | ~R 25 420 indirect | — |
IAP Variant #01 | — | R 23 567 | 8d | — | — | ~1 | ~R 23 567 indirect | — |
CLARA Variant #01 Partial | — | R 19 971 | 35d | — | — | ~1 | ~R 19 971 indirect | — |
HAM Variant #01 | — | R 15 692 | — | — | — | ~1 | ~R 15 692 indirect | — |
ADE (standard-dose Ara-C) Variant #07 | — | R 13 353 | 10d | — | — | 1 | R 13 353 PFS proxy | 1 |
Etoposide and Mitoxantrone Variant #01 | — | R 12 244 | — | — | — | ~1 | ~R 12 244 indirect | — |
MEC Variant #01 | — | R 9 564 | 28d | — | 5.4 mo | 1 | R 9 564 PFS proxy | 3 |
5+2d Variant #01 | — | R 6 806 | 5d | — | — | ~1 | ~R 6 806 indirect | — |
Cytarabine and Vosaroxin Variant #01 Partial | — | R 3 900 | 28d | — | ~7.5 mo | ~3 | ~R 11 699 PFS proxy · indirect | 1 |
High-dose Cytarabine monotherapy (HiDAC) Variant #01 | — | R 3 498 | — | — | ~60.0 mo | ~1 | ~R 3 498 PFS proxy · indirect | — |
Intermediate-dose Cytarabine monotherapy (IDAC) Variant #01 | — | R 1 560 | 28d | — | 7.6 mo | 6 | R 9 359 PFS proxy | 1 |
Clofarabine and Cytarabine Variant #01 Partial | — | R 892 | — | — | 6.6 mo | 4 | R 3 567 PFS proxy | 1 |
20 of 20 regimens shown